Bill's Feed
Jan 7, 2015

Halozyme CEO sees blockbuster potential in its cancer drug

NEW YORK, Jan 7 (Reuters) – Halozyme Therapeutics Inc
believes it has a multibillion-dollar cancer drug on
its hands.

The drug, PEGPH20, being tested against pancreatic cancer,
has the potential to help treat several other types of solid
tumor cancers, its chief executive said in an interview.

Jan 5, 2015

CVS to cover Gilead hepatitis C treatment over AbbVie regimen

Jan 5 (Reuters) – CVS Health Corp, one of the
largest U.S. managers of drug benefits, said it would give
preferred status to the hepatitis C treatments from Gilead
Sciences and cover a new competing treatment from
AbbVie Inc only as an exception.

The latest salvo in the battle to grab market share for new
all-oral treatments for the liver-destroying hepatitis C virus
follows a move last month by CVS rival Express Scripts Holding
that favored AbbVie’s regimen after negotiating a price
discount below what Gilead had been charging its commercial

Dec 11, 2014

Nestle invests more in skin care strategy with 10 research centers

By Bill Berkrot

(Reuters) – Nestle on Thursday will announce plans to open 10 skin care research centers worldwide, deepening its investment in a faster-growing market for healthcare products.

The Swiss company, known globally for its chocolate bars, baby food and coffee, signaled a heightened interest in skin care earlier this year. It spent $5.7 billion for the rights to some injectable wrinkle treatments of Valeant Pharmaceuticals and for L’Oreal’s share of a dermatology joint venture the two operated.

Dec 11, 2014

Shire CEO eyes deals, but no urgency to spend AbbVie breakup fee

NEW YORK (Reuters) – Shire PLC’s (SHP.L: Quote, Profile, Research, Stock Buzz) chief executive said he sees no urgency to spend the windfall the Dublin-based drugmaker received when AbbVie (ABBV.N: Quote, Profile, Research, Stock Buzz) walked away from a $55 billion takeover bid earlier this year.

AbbVie scuttled the so-called inversion deal in October after changes in U.S. tax rules aimed at preventing U.S. companies from redomiciling abroad to take advantage of lower corporate taxes.

Dec 8, 2014

Edwards CEO hopes FDA to accelerate approvals of medical devices

NEW YORK (Reuters) – U.S. health regulators appear open to speeding up approvals of medical devices that currently often reach European markets three to five years ahead of being cleared in the United States, the chief executive officer of Edwards Lifesciences said.

Such a change could help get the third generation of its Sapien transcatheter aortic heart valve replacement (TAVR) to U.S. clinicians faster than previously expected, Edwards CEO Michael Mussallem told Reuters on Monday following the company’s business update for analysts and investors in New York.

Dec 6, 2014

High rate of lymphoma patients respond to Bristol-Myers drug: study

By Bill Berkrot

(Reuters) – Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday.

The study of Bristol-Myers’ immunotherapy drug nivolumab involved 23 patients whose lymphoma had progressed after numerous prior treatments, including chemotherapy, stem cell transplants and the Seattle Genetics drug Adcetris.

Dec 6, 2014

Merck immunotherapy drug shows promise against lymphoma -study

Dec 6 (Reuters) – Merck & Co Inc’s drug that
harnesses the immune system to fight cancer showed promise in
Hodgkin lymphoma patients whose disease had progressed following
prior therapies, according to data from a small, early stage
trial being presented at a medical meeting.

In the ongoing study of 29 patients, 66 percent had a
meaningful response to the drug, Keytruda, after 24 weeks of
treatment, including six patients (21 percent) who achieved
complete remission.

Dec 6, 2014

Addition of Amgen drug boosts benefits in relapsed myeloma -study

Dec 6 (Reuters) – Significantly more patients with relapsed
multiple myeloma responded to a three-drug regimen including
Amgen Inc’s Kyprolis than those who got the standard
two-drug treatment, according to results from a late-stage

Patients with the blood cancer who received the Kyprolis
regimen for 18 months also had a longer duration of response and
reported better health-related quality of life, data presented
on Saturday showed.

Dec 3, 2014

U.S. FDA approves Amgen leukemia drug ahead of schedule

By Bill Berkrot

(Reuters) – U.S. health regulators on Wednesday approved an Amgen Inc drug that helps the immune system fight a rare type of leukemia, more than five months ahead of the expected decision date.

The drug, blinatumomab, which will be sold under the brand name Blincyto, was approved to treat a form of acute lymphoblastic leukemia (ALL) for which there are few treatment options once a patient has relapsed.

Nov 24, 2014

Roche’s Genentech defends supply shift for top cancer drugs

Nov 24 (Reuters) – Genentech, U.S. biotech unit of Roche
Holding, faces growing pressure over a decision to
allow only a handful of distributors to supply three of the
world’s most widely used cancer drugs, a move that prominent
hospitals say will create delays and raise costs.

Genentech in October began distributing Avastin, Herceptin
and Rituxan to hospitals and clinics through six specialty drug
distributors, rather than through drug wholesalers, which
distribute a wide range of medicines, devices and equipment on
an enormous scale. Specialty distributors supply biologic
infusion medicines that often require special storage and

    • About Bill

      "Based in New York, I primarily cover the pharmaceutical and biotechnology sectors as well as other publicly traded companies involved in health care. Previously covered a wide range of sports for Reuters."
    • Follow Bill